### RETRACTION

# UPFI Participates in the Progression of Endometrial Cancer by Inhibiting the Expression of IncRNA PVTI [Retraction]

Xing T, Chen P, Wu J, et al. Onco Targets Ther. 2020;13:2103-2114.

We, the Editors and Publisher of OncoTargets and Therapy, have retracted the following article.

Following publication of the article, concerns were raised about the duplication of images from Figures 2 and 3 with images from other unrelated articles. Specifically,

- Images for Figure 2D and 2H have been duplicated with images for Figure 1e from Liu S, Liu LH, Hu WW, Wang M. Long noncoding RNA TUG1 regulates the development of oral squamous cell carcinoma through sponging miR-524-5p to mediate DLX1 expression as a competitive endogenous RNA. *J Cell Physiol*. 2019;234:20206–20216. <u>https://doi.org/10.1002/jcp.28620</u> and Figure 2E and 7F from Chen Y, Lei Y, Lin J, et al. The LINC01260 Functions as a Tumor Suppressor via the miR-562/CYLD/NF-κB Pathway in Non-Small Cell Lung Cancer. *Onco Targets Ther*. 2020;13:10707-10719. https://doi.org/10.2147/OTT.S253730 (RETRACTED).
- Images for Figure 3D and 3H have been duplicated with images for Figure 1f from Liu et al, 2019 and Figures 3b and 5g from Xiong Y, Zhang J, Song C. CircRNA ZNF609 functions as a competitive endogenous RNA to regulate FOXP4 expression by sponging miR-138-5p in renal carcinoma. *J Cell Physiol*. 2019;234:10646–10654. <u>https://doi.org/10.1002/jcp.27744</u>.
- In addition, images for Figure 6D, si NC and 6H, NC have been duplicated with images for Figure 7D, siUPF1 and siUPF1+siPVT1, respectively.

The authors did not respond to our queries and were unable to provide an explanation for the duplicated images or provide data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

#### **OncoTargets and Therapy**

**Dove**press

5

## Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S460241

Received: 18 January 2024 Accepted: 18 January 2024 Published: 19 January 2024

#### OncoTargets and Therapy 2024:17 5

© 2024 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. for permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).